Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Hua Chen and Rajender Aparasu.
Hua Chen
Connection Strength
7.635
Rajender Aparasu
  1. Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists. J Child Adolesc Psychopharmacol. 2024 10; 34(8):359-365.
    View in: PubMed
    Score: 0.240
  2. Pain-related hospitalization and emergency room visit following initial analgesic prescription after outpatient surgery. Pharmacoepidemiol Drug Saf. 2024 02; 33(2):e5759.
    View in: PubMed
    Score: 0.231
  3. Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking Second-Generation Antipsychotics. Psychiatr Serv. 2024 Apr 01; 75(4):342-348.
    View in: PubMed
    Score: 0.225
  4. Trends in Repeat Opioid Analgesic Prescription Utilization for Acute Pain in Children: 2013-2018. Acad Pediatr. 2024 07; 24(5):776-782.
    View in: PubMed
    Score: 0.225
  5. Association Between Abnormal Metabolic Parameters and Receiving Subsequent Interventions in Children and Adolescents Initiating Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2023 09; 33(7):269-278.
    View in: PubMed
    Score: 0.224
  6. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clin Ther. 2023 09; 45(9):e177-e186.
    View in: PubMed
    Score: 0.223
  7. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study. Clin Rheumatol. 2024 Jan; 43(1):103-116.
    View in: PubMed
    Score: 0.223
  8. Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents. J Psychiatr Res. 2023 09; 165:170-173.
    View in: PubMed
    Score: 0.222
  9. Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis. Explor Res Clin Soc Pharm. 2023 Sep; 11:100296.
    View in: PubMed
    Score: 0.221
  10. Association Between Initial Opioid Prescription Duration and 30-Day Risk of Receiving Repeat Opioid Among Children. Acad Pediatr. 2023 03; 23(2):416-424.
    View in: PubMed
    Score: 0.207
  11. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs Aging. 2022 06; 39(6):453-465.
    View in: PubMed
    Score: 0.206
  12. Risk of overactive bladder associated with cholinesterase inhibitors in dementia. J Am Geriatr Soc. 2022 03; 70(3):820-830.
    View in: PubMed
    Score: 0.198
  13. Impact of geographic access to primary care providers on pediatric behavioral health screening. Prev Med. 2021 12; 153:106856.
    View in: PubMed
    Score: 0.197
  14. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Curr Med Res Opin. 2021 08; 37(8):1303-1313.
    View in: PubMed
    Score: 0.191
  15. Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis. Explor Res Clin Soc Pharm. 2021 Jun; 2:100021.
    View in: PubMed
    Score: 0.191
  16. Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study. Drugs Aging. 2021 06; 38(6):493-502.
    View in: PubMed
    Score: 0.189
  17. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
    View in: PubMed
    Score: 0.189
  18. Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. Int J Geriatr Psychiatry. 2021 05; 36(5):684-696.
    View in: PubMed
    Score: 0.185
  19. Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis. Patient Prefer Adherence. 2020; 14:2187-2199.
    View in: PubMed
    Score: 0.184
  20. Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease. Am J Geriatr Psychiatry. 2020 10; 28(10):1079-1088.
    View in: PubMed
    Score: 0.175
  21. Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. J Gen Intern Med. 2020 07; 35(7):2084-2093.
    View in: PubMed
    Score: 0.175
  22. Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson's Disease and Comorbid Depression. Drug Healthc Patient Saf. 2020; 12:23-30.
    View in: PubMed
    Score: 0.175
  23. Racial/ethnic differences in treatment quality among youth with primary care provider-initiated versus mental health specialist-initiated care for major depressive disorders. Child Adolesc Ment Health. 2020 02; 25(1):28-35.
    View in: PubMed
    Score: 0.173
  24. Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease. J Psychiatr Res. 2019 10; 117:116-121.
    View in: PubMed
    Score: 0.169
  25. Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression. Res Social Adm Pharm. 2020 03; 16(3):329-335.
    View in: PubMed
    Score: 0.167
  26. Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders. Psychiatry Res. 2019 06; 276:151-159.
    View in: PubMed
    Score: 0.166
  27. The association between geographic access to providers and the treatment quality of pediatric depression. J Affect Disord. 2019 06 15; 253:162-170.
    View in: PubMed
    Score: 0.166
  28. Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. J Manag Care Spec Pharm. 2019 Jan; 25(1):29-38.
    View in: PubMed
    Score: 0.162
  29. Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders. Res Social Adm Pharm. 2019 04; 15(4):395-403.
    View in: PubMed
    Score: 0.156
  30. Racial/ethnic differences in the treatment of adolescent major depressive disorders (MDD) across healthcare providers participating in the medicaid program. J Affect Disord. 2018 08 01; 235:155-161.
    View in: PubMed
    Score: 0.154
  31. Risk of Mortality Associated with Anticholinergic Use in Elderly Nursing Home Residents with Depression. Drugs Aging. 2017 09; 34(9):691-700.
    View in: PubMed
    Score: 0.148
  32. Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders. J Child Adolesc Psychopharmacol. 2017 May; 27(4):349-358.
    View in: PubMed
    Score: 0.144
  33. The Impact of Pharmacotherapy on Substance Use in Adolescents With Attention-Deficit/Hyperactivity Disorder: Variations Across Subtypes. Subst Use Misuse. 2017 08 24; 52(10):1266-1274.
    View in: PubMed
    Score: 0.143
  34. Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. Pharmacotherapy. 2017 03; 37(3):287-296.
    View in: PubMed
    Score: 0.143
  35. Care Provision and Prescribing Practices of Physicians Treating Children and Adolescents With ADHD. Psychiatr Serv. 2017 Jul 01; 68(7):681-688.
    View in: PubMed
    Score: 0.142
  36. Risk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With Depression. Am J Alzheimers Dis Other Demen. 2016 12; 31(8):678-686.
    View in: PubMed
    Score: 0.139
  37. Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors. J Comp Eff Res. 2016 08; 5(5):461-73.
    View in: PubMed
    Score: 0.137
  38. Anticholinergic Medication Use and Risk of Fracture in Elderly Adults with Depression. J Am Geriatr Soc. 2016 07; 64(7):1492-7.
    View in: PubMed
    Score: 0.136
  39. Anticholinergic Medication Use and Risk of Dementia Among Elderly Nursing Home Residents with Depression. Am J Geriatr Psychiatry. 2016 06; 24(6):485-95.
    View in: PubMed
    Score: 0.133
  40. Anticholinergic Medication Use and Risk of Pneumonia in Elderly Adults: A Nested Case-Control Study. J Am Geriatr Soc. 2016 Feb; 64(2):394-400.
    View in: PubMed
    Score: 0.132
  41. Comparative Effectiveness of Second-Generation Antidepressants in Reducing the Risk of Dementia in Elderly Nursing Home Residents with Depression. Pharmacotherapy. 2016 Jan; 36(1):38-48.
    View in: PubMed
    Score: 0.132
  42. Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With Depression. Ann Pharmacother. 2016 Feb; 50(2):96-105.
    View in: PubMed
    Score: 0.131
  43. Factors associated with the use of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease: A SEER-Medicare study. J Geriatr Oncol. 2024 11; 15(8):102071.
    View in: PubMed
    Score: 0.060
  44. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019 04 01; 125(7):1155-1162.
    View in: PubMed
    Score: 0.041
  45. Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension. J Alzheimers Dis. 2016; 49(2):423-32.
    View in: PubMed
    Score: 0.033
  46. Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure. Am J Alzheimers Dis Other Demen. 2016 08; 31(5):395-404.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.